AR110193A1 - Análogos de insulina de acción rápida de estabilidad mejorada - Google Patents
Análogos de insulina de acción rápida de estabilidad mejoradaInfo
- Publication number
- AR110193A1 AR110193A1 ARP170103233A ARP170103233A AR110193A1 AR 110193 A1 AR110193 A1 AR 110193A1 AR P170103233 A ARP170103233 A AR P170103233A AR P170103233 A ARP170103233 A AR P170103233A AR 110193 A1 AR110193 A1 AR 110193A1
- Authority
- AR
- Argentina
- Prior art keywords
- glu
- substitution
- chain
- insulin analog
- chain polypeptide
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000004026 insulin derivative Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 238000006467 substitution reaction Methods 0.000 abstract 4
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000002144 chemical decomposition reaction Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
Un análogo de insulina de dos cadenas contiene un polipéptido de cadena A modificado y un polipéptido de cadena B modificado. El polipéptido de la cadena A comprende uno o más de: una sustitución de His o Glu en la posición A⁸, una sustitución de Glu en la posición A¹⁴; y una sustitución de Gln o Arg en la posición A¹⁷. El polipéptido de cadena B comprende uno o más de: una deleción de los aminoácidos en la posición B¹, B¹-B², B¹-B³, B³⁰ o una combinación de los mismos; una sustitución de Ala o Glu en la posición B²; una sustitución de Glu en la posición B³. El análogo de insulina exhibe estabilidad termodinámica en una solución libre de zinc, disminución de la autoasociación, mantiene la potencia biológica y no presenta una mitogénesis potenciada. El análogo de insulina exhibe resistencia a la degradación química y resistencia a la degradación física. Un método para tratar pacientes con diabetes mellitus u obesidad comprende la administración de una cantidad fisiológicamente eficaz del análogo de insulina o una sal fisiológicamente aceptable del mismo al paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424892P | 2016-11-21 | 2016-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110193A1 true AR110193A1 (es) | 2019-03-06 |
Family
ID=62145846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103233A AR110193A1 (es) | 2016-11-21 | 2017-11-21 | Análogos de insulina de acción rápida de estabilidad mejorada |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11208453B2 (es) |
| EP (1) | EP3541397A4 (es) |
| JP (1) | JP7286160B2 (es) |
| KR (1) | KR20190101963A (es) |
| CN (1) | CN110198722A (es) |
| AR (1) | AR110193A1 (es) |
| AU (1) | AU2017361524B2 (es) |
| CA (1) | CA3044565A1 (es) |
| MY (1) | MY200047A (es) |
| TW (1) | TW201831504A (es) |
| UY (1) | UY37490A (es) |
| WO (1) | WO2018094388A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166223A (zh) * | 2018-09-21 | 2021-07-23 | 卡斯西部储备大学 | 位点2单链胰岛素类似物 |
| EP3893934B1 (en) | 2018-12-11 | 2025-09-10 | Sanofi | Insulin conjugates |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| CA3170615A1 (en) * | 2020-03-02 | 2021-09-10 | Thermalin Inc. | Compositions containing rapid-acting insulin analogues |
| US12385818B2 (en) | 2023-02-14 | 2025-08-12 | Saudi Arabian Oil Company | Modeling gas desorption in a subsurface reservoir |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK33591D0 (es) * | 1991-02-27 | 1991-02-27 | Novo Nordisk As | |
| EP1453860A2 (en) * | 2001-12-02 | 2004-09-08 | Novo Nordisk A/S | Novel glucose-dependant insulins |
| CN101243190B (zh) * | 2005-08-16 | 2015-05-13 | 诺沃-诺迪斯克有限公司 | 制备成熟胰岛素多肽的方法 |
| CN101796071A (zh) * | 2007-08-13 | 2010-08-04 | 诺沃-诺迪斯克有限公司 | 快速作用的胰岛素类似物 |
| EP2178912B1 (en) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| CN101970477B (zh) * | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| RU2010147076A (ru) * | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
| PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
| WO2011159882A2 (en) * | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Novel stabilized insulin agonists |
| WO2011159895A2 (en) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| EP2804621A4 (en) * | 2012-01-20 | 2015-11-18 | Univ Case Western Reserve | GLUTAMINE-SAFE STABILIZED INSULIN ANALOG |
| WO2014116753A1 (en) * | 2013-01-22 | 2014-07-31 | Case Western Reserve University | N-terminal truncated insulin analogues |
| BR112015023672A2 (pt) | 2013-03-15 | 2017-07-18 | Univ Case Western Reserve | análogo de insulina, orto-fluoro, sequência de dna codificando a cadeia a de análogo de insulina, sequência de dna codificando a cadeia b de análogo de insulina e uso de um análogo de insulina. |
| BR112016016290A2 (pt) | 2014-01-13 | 2017-10-03 | Thermalin Diabetes Llc | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US10392429B2 (en) * | 2014-10-06 | 2019-08-27 | Case Western Reserve University | Biphasic single-chain insulin analogues |
| CA2964918A1 (en) * | 2014-10-20 | 2016-04-28 | Case Western Reserve University | Halogenated insulin analogues of enhanced biological potency |
| JP2018505874A (ja) * | 2015-01-20 | 2018-03-01 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 選択的シグナリング特性及びより低い分裂促進性を有するインスリンアナログ |
-
2017
- 2017-11-21 US US16/462,440 patent/US11208453B2/en active Active
- 2017-11-21 CA CA3044565A patent/CA3044565A1/en active Pending
- 2017-11-21 EP EP17871148.7A patent/EP3541397A4/en active Pending
- 2017-11-21 KR KR1020197015429A patent/KR20190101963A/ko not_active Withdrawn
- 2017-11-21 UY UY0001037490A patent/UY37490A/es not_active Application Discontinuation
- 2017-11-21 JP JP2019527187A patent/JP7286160B2/ja active Active
- 2017-11-21 AU AU2017361524A patent/AU2017361524B2/en not_active Ceased
- 2017-11-21 CN CN201780084102.8A patent/CN110198722A/zh active Pending
- 2017-11-21 WO PCT/US2017/062772 patent/WO2018094388A1/en not_active Ceased
- 2017-11-21 TW TW106140371A patent/TW201831504A/zh unknown
- 2017-11-21 AR ARP170103233A patent/AR110193A1/es unknown
- 2017-11-21 MY MYPI2019002836A patent/MY200047A/en unknown
-
2021
- 2021-12-27 US US17/562,435 patent/US12312390B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3541397A1 (en) | 2019-09-25 |
| MY200047A (en) | 2023-12-06 |
| AU2017361524A1 (en) | 2019-06-20 |
| US12312390B2 (en) | 2025-05-27 |
| US11208453B2 (en) | 2021-12-28 |
| UY37490A (es) | 2018-06-29 |
| JP7286160B2 (ja) | 2023-06-05 |
| AU2017361524B2 (en) | 2022-06-02 |
| JP2019535733A (ja) | 2019-12-12 |
| US20190322719A1 (en) | 2019-10-24 |
| CN110198722A (zh) | 2019-09-03 |
| EP3541397A4 (en) | 2020-11-04 |
| WO2018094388A1 (en) | 2018-05-24 |
| KR20190101963A (ko) | 2019-09-02 |
| US20220112262A1 (en) | 2022-04-14 |
| CA3044565A1 (en) | 2018-05-24 |
| TW201831504A (zh) | 2018-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110193A1 (es) | Análogos de insulina de acción rápida de estabilidad mejorada | |
| HRP20211415T1 (hr) | Brzodjelujući pripravci inzulina | |
| PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
| AR081200A1 (es) | Formulaciones de insulina de accion prolongada | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| PE20121362A1 (es) | Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| AR053495A1 (es) | Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| PE20091305A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| JP2011241213A5 (es) | ||
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| MX389091B (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2. | |
| WO2009129250A3 (en) | Meal-time insulin analogues of enhanced stability | |
| PE20151808A1 (es) | Peptidos terapeuticos | |
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| MX2017008569A (es) | Derivados de glucagon con estabilidad mejorada. | |
| MY181626A (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| WO2016105545A3 (en) | Insulin analogues with enhanced stabilized and reduced mitogenicity | |
| SA522432563B1 (ar) | نظير ببتيد أوكسينتو موديولين معالج بأسيل | |
| AR097613A1 (es) | Dosificación de péptidos co-antagonistas gip/glp-1 para administración a humanos | |
| MX2023015068A (es) | Analogo de glucagon y uso medico del mismo. | |
| RU2022119802A (ru) | Композиции инсулинов длительного действия |